Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850622 | 0.89 | SNCA (0.86) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL1208152 | 0.89 | SNCA (0.86) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL21752000 | 0.83 | SNCA (1.00) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL19398391 | 0.83 | SNCA (0.76) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL21751995 | 0.80 | SNCA (1.00) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL21771119 | 0.74 | SNCA (0.71) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL8226190 | 0.73 | SNCA (0.67) | SNCAMAPTGAANOX1SIRT2 | |
| SCHEMBL8226386 | 0.72 | SNCA (0.78) | SNCAMAPTGAANOX1SIRT2 | |
| SCHEMBL17999732 | 0.71 | SNCA (0.84) | SNCAMAPTLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL17999733 | 0.71 | SNCA (0.84) | SNCAMAPTLMNAMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907804-B2 | Phenothiazine diaminium salts and their use | WISTA LABORATORIES LTD. (SG) | 2018-03-06 | — | — | US | disclosed |
| US-20160237048-A1 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE | WISTA LABORATORIES LTD. (SG) | 2016-08-18 | — | — | US | disclosed |
| US-20160237048-A1 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE | WISTA LABORATORIES LTD. (SG) | 2016-08-18 | — | — | US | disclosed |
| EP-2673266-B1 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE | WISTA LAB LTD (SG) | 2016-07-27 | — | — | EP | disclosed |
| US-9283230-B2 | Phenothiazine diaminium salts and their use | WISTA LABORATORIES LTD. (SG) | 2016-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237048-A1 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE | QDPR, SLC35A1, SLC6A7 | SNCA 427/4885MAPT 184/4885LMNA 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.